Skip to content
Life Sciences Series A Founded 2015

NaNotics

Developer of nanomedical platform for treating major human and animal diseases. Its products remove the molecular signals or signal inhibitors that assist disease progression and are later cleared from the body via phagocytosis. It has features including nanoparticles made of biocompatible materials, the inclusion of a binding-capture agent, and the shielding of the capture agent with cell membrane receptors.…

📍 Mill Valley, United States · Oncology,

Funding snapshot

Last roundSeries A
Amount$2M
Date13 August 2025
Total raised$10M
Team size7

About

Developer of nanomedical platform for treating major human and animal diseases. Its products remove the molecular signals or signal inhibitors that assist disease progression and are later cleared from the body via phagocytosis. It has features including nanoparticles made of biocompatible materials, the inclusion of a binding-capture agent, and the shielding of the capture agent with cell membrane receptors. Founded in 2015, headquartered in Mill Valley, United States. The company has raised $10M at the Series A stage backed by investors including LifeSpan Vision Ventures, HHS, Lauder Partners, quadraScope, Melnichek Investments. Operating in Life Sciences > Oncology, Life Sciences > Drug Delivery.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation,

Oncology > Drugs > Diversified,

Drug Delivery > Nanoparticle Based

Institutional investors

LifeSpan Vision Ventures HHS Lauder Partners quadraScope Melnichek Investments

Latest coverage

No articles yet.

Raising like NaNotics?

Analyze your pitch deck before your next raise.

Analyze My Deck →